اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها3,019
تعداد مقالات33,734
تعداد مشاهده مقاله44,974,861
تعداد دریافت فایل اصل مقاله46,501,074
Karimian, Mohammad, Behjati, Mohaddeseh, Mohammadi, Amir Hossein. (1404). COVID-19 and ACE2 receptor in different tissues: From pathophysiologic function to therapeutic responses. سامانه مدیریت نشریات علمی, 80(3), 691-704. doi: 10.32592/ARI.2025.80.3.691
Mohammad Karimian; Mohaddeseh Behjati; Amir Hossein Mohammadi. "COVID-19 and ACE2 receptor in different tissues: From pathophysiologic function to therapeutic responses". سامانه مدیریت نشریات علمی, 80, 3, 1404, 691-704. doi: 10.32592/ARI.2025.80.3.691
Karimian, Mohammad, Behjati, Mohaddeseh, Mohammadi, Amir Hossein. (1404). 'COVID-19 and ACE2 receptor in different tissues: From pathophysiologic function to therapeutic responses', سامانه مدیریت نشریات علمی, 80(3), pp. 691-704. doi: 10.32592/ARI.2025.80.3.691
Karimian, Mohammad, Behjati, Mohaddeseh, Mohammadi, Amir Hossein. COVID-19 and ACE2 receptor in different tissues: From pathophysiologic function to therapeutic responses. سامانه مدیریت نشریات علمی, 1404; 80(3): 691-704. doi: 10.32592/ARI.2025.80.3.691

COVID-19 and ACE2 receptor in different tissues: From pathophysiologic function to therapeutic responses

Archives of Razi Institute
مقاله 6، دوره 80، شماره 3، مرداد و شهریور 2025، صفحه 691-704    اصل مقاله (589.03 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.3.691
نویسندگان
Mohammad Karimian* 1؛ Mohaddeseh Behjati2؛ Amir Hossein Mohammadi3
1Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran.
2Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
3Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
چکیده
SARS-CoV-2, the virus responsible for COVID-19, is characterized by its high transmission rate, leading to a global pandemic. Millions of people have lost their lives due to the infection caused by this virus. The ability of the virus to spread rapidly and infect large numbers of people has highlighted the need to understand its infection mechanisms. Angiotensin-converting enzyme 2 (ACE2) is an essential receptor for SARS-CoV-2 cell entry. SARS-CoV-2 shows high affinity to this receptor and shows high infectivity, which leads to an explosive increase of this virus in patients infected with COVID-19. ACE2 is the carboxypeptidase homolog of ACE, which produces angiotensin II, the main active peptide of the renin-angiotensin system. From a pathophysiological perspective, this system regulates vital processes in different organs. In addition, ACE2 enzyme activity could play a protective role against acute respiratory distress syndrome (ARDS) caused by viral pneumonia. Upon infection, SARS-CoV-2 down-regulates the expression of ACE2, which is possibly related to the ARDS pathogenesis. Since this receptor is present in various other tissues such as the heart, kidney, gastrointestinal tract, reproductive system, and sensory organs, it may cause pathological symptoms in these organs. Thus, ACE2 is not only a receptor for SARS-CoV-2 but may play a crucial role in various aspects of the pathogenesis of COVID-19 and possible post-COVID-19 syndromes. Administering ACE2 may competitively bind to SARS-CoV, thereby preventing the viral spike protein from attaching to the transmembrane ACE2 and consequently reducing viral cell entry and COVID-19 symptoms. Here, we first review the role of ACE2 in the pathophysiology of SARS-CoV-2 across different tissues and propose treatment strategies for COVID-19 that involve ACE2.
کلیدواژه‌ها
ACE2؛ COVID-19؛ Renin-angiotensin-aldosterone system؛ SARS-CoV-2
عنوان مقاله [English]
گیرنده COVID-19 و ACE2 در بافت های مختلف: از عملکرد پاتوفیزیولوژیک تا پاسخ های درمانی
چکیده [English]
ویروس SARS-CoV-2، عامل بیماری COVID-19، با نرخ انتقال بالای خود که منجر به یک پاندمی جهانی شده، شناخته می‌شود. میلیون‌ها نفر جان خود را به دلیل عفونت ناشی از این ویروس از دست داده‌اند. توانایی این ویروس در انتشار سریع و آلوده کردن تعداد زیادی از افراد، نیاز به درک مکانیسم‌های عفونت آن را برجسته کرده است. آنزیم مبدل آنژیوتانسین 2 (ACE2) یک گیرنده ضروری برای ورود SARS-CoV-2 به سلول‌ها است. SARS-CoV-2 نشان‌دهنده تمایل بالایی به این گیرنده است و عفونت‌زایی بالایی دارد، که منجر به افزایش انفجاری این ویروس در بیماران مبتلا به COVID-19 می‌شود. ACE2 یک کاربوکسی‌پپتیداز همولوگ از ACE است که آنژیوتانسین II را تولید می‌کند، که پپتید اصلی فعال سیستم رنین-آنژیوتانسین است. از دیدگاه پاتوفیزیولوژیک، این سیستم فرآیندهای حیاتی در اندام‌های مختلف را تنظیم می‌کند. علاوه بر این، فعالیت آنزیم ACE2 ممکن است نقش محافظتی در برابر سندرم دیسترس حاد تنفسی (ARDS) ناشی از ذات‌الریه ویروسی داشته باشد. پس از عفونت، SARS-CoV-2 بیان ACE2 را کاهش می‌دهد که احتمالاً با پاتوژنز ARDS مرتبط است. از آنجایی که این گیرنده در بافت‌های مختلف دیگری نظیر قلب، کلیه، دستگاه گوارش، سیستم تولیدمثل، و اندام‌های حسی نیز حضور دارد، ممکن است باعث بروز علائم پاتولوژیک در این اندام‌ها شود. بنابراین، ACE2 نه تنها به عنوان گیرنده‌ای برای SARS-CoV-2 عمل می‌کند، بلکه ممکن است در جنبه‌های مختلف پاتوژنز COVID-19 و سندرم‌های احتمالی پس از COVID-19 نقش مهمی ایفا کند. تجویز ACE2 ممکن است به صورت رقابتی به SARS-CoV متصل شود و از اتصال پروتئین اسپایک ویروسی به ACE2 غشایی جلوگیری کرده و در نتیجه ورود ویروس به سلول و علائم COVID-19 را کاهش دهد. در اینجا، ابتدا نقش ACE2 در پاتوفیزیولوژی SARS-CoV-2 در بافت‌های مختلف را مرور می‌کنیم و استراتژی‌های درمانی برای COVID-19 که شامل ACE2 هستند را پیشنهاد می‌دهیم.
کلیدواژه‌ها [English]
ACE2, کووید 19, سیستم رنین-آنژیوتانسین-آلدوسترون, SARS-CoV-2
مراجع
  1. Ashraf UM, Abokor AA, Edwards JM, Waigi EW, Royfman RS, Hasan SA, et al. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiological genomics. 2021;53(2):51-60.
  2. Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Journal of molecular and cellular cardiology. 2020;144:47-53.
  3. Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC medicine. 2020;18:1-8.
  4. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature reviews Microbiology. 2021;19(3):141-54.
  5. Kosari M, Khorvash F, Sayyah MK, Ansari Chaharsoughi M, Najafi A, Momen‐Heravi M, et al. The influence of propolis plus Hyoscyamus niger L. against COVID‐19: A phase II, multicenter, placebo‐controlled, randomized trial. Phytotherapy Research. 2024;38(1):400-10.
  6. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535-8.
  7. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. European journal of clinical microbiology & infectious diseases. 2021;40(5):905-19.
  8. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8.
  9. Karimian A, Behjati M, Karimian M. Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2. Archives of virology. 2022;167(10):1931-46.
  10. Wang LL, Yang JW, Xu JF. Severe acute respiratory syndrome coronavirus 2 causes lung inflammation and injury. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022;28(4):513-20.
  11. Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, et al. Novel insights on the pulmonary vascular consequences of COVID-19. American journal of physiology Lung cellular and molecular physiology. 2020;319(2):L277-l88.
  12. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017;94:317-25.
  13. Simões e Silva A, Silveira K, Ferreira A, Teixeira M. ACE2, angiotensin‐(1‐7) and M as receptor axis in inflammation and fibrosis. British journal of pharmacology. 2013;169(3):477-92.
  14. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clinical science (London, England : 1979). 2020;134(5):543-5.
  15. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, et al. The emerging role of ACE2 in physiology and disease. The Journal of pathology. 2007;212(1):1-11.
  16. Raygan F, Karimian M, Rezaeian A, Bahmani B, Behjati M. Angiotensinogen-M235T as a risk factor for myocardial infarction in Asian populations: a genetic association study and a bioinformatics approach. Croatian medical journal. 2016;57(4):351-62.
  17. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. American journal of physiology Heart and circulatory physiology. 2020;318(5):H1084-h90.
  18. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Current opinion in pharmacology. 2006;6(3):271-6.
  19. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). The Journal of pathology. 2020;251(3):228-48.
  20. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223):507-13.
  21. Vetta F, Vetta G, Marinaccio L. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a vicious circle. J Cardiol Cardiovasc Res. 2020;1(2):1-12.
  22. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research. 2020;116(6):1097-100.
  23. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. The American journal of pathology. 2006;168(6):1808-20.
  24. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circulation research. 2020;126(10):1456-74.
  25. Chen C-Y, Lin M-W, Xie X-Y, Lin C-H, Yang C-W, Wu P-C, et al. Studying the Roles of the Renin–Angiotensin System in Accelerating the Disease of High-Fat-Diet-Induced Diabetic Nephropathy in a db/db and ACE2 Double-Gene-Knockout Mouse Model. International journal of molecular sciences. 2023;25(1):329.
  26. Hashimoto T, Sakata Y, Fukushima K, Maeda T, Arita Y, Shioyama W, et al. Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection. Internal medicine (Tokyo, Japan). 2011;50(2):119-24.
  27. Hernández VS, Zetter MA, Guerra EC, Hernández-Araiza I, Karuzin N, Hernández-Pérez OR, et al. ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations. Experimental neurology. 2021;345:113837.
  28. Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487(7408):477-81.
  29. Durairajan SSK, Singh AK, Saravanan UB, Namachivayam M, Radhakrishnan M, Huang JD, et al. Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications. Viruses. 2023;15(6).
  30. Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. Acta physiologica (Oxford, England). 2021;233(4):e13733.
  31. Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19. Liver international : official journal of the International Association for the Study of the Liver. 2020;40(8):2038-40.
  32. Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clinical science (London, England : 1979). 2020;134(23):3137-58.
  33. Cococcia S, Lenti MV, Santacroce G, Achilli G, Borrelli de Andreis F, Di Sabatino A. Liver-spleen axis dysfunction in COVID-19. World journal of gastroenterology. 2021;27(35):5919-31.
  34. Wang NP, Erskine J, Zhang WW, Zheng RH, Zhang LH, Duron G, et al. Recruitment of macrophages from the spleen contributes to myocardial fibrosis and hypertension induced by angiotensin II. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2017;18(2):1470320317706653.
  35. Ping H, Zhang K, Wang Y, Tong X, Chen Z, Cai C, et al. Cell death and pathological findings of the spleen in COVID-19 patients. Pathology, research and practice. 2021;227:153610.
  36. Salamanna F, Maglio M, Landini MP, Fini M. Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. Frontiers in medicine. 2020;7:594495.
  37. Liao X, Xiao J, Li S-H, Xiao L-L, Cheng B, Fu X-B, et al. Critical role of the endogenous renin-angiotensin system in maintaining self-renewal and regeneration potential of epidermal stem cells. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2019;1865(10):2647-56.
  38. Narayan SS, Lorenz K, Ukkat J, Hoang-Vu C, Trojanowicz B. Angiotensin converting enzymes ACE and ACE2 in thyroid cancer progression. Neoplasma. 2020;67(2):402-9.
  39. Tao H, Bai J, Zhang W, Zheng K, Guan P, Ge G, et al. Bone biology and COVID-19 infection: Is ACE2 a potential influence factor? Medical hypotheses. 2020;144:110178.
  40. Gao J, Mei H, Sun J, Li H, Huang Y, Tang Y, et al. Neuropilin-1-Mediated SARS-CoV-2 Infection in Bone Marrow-Derived Macrophages Inhibits Osteoclast Differentiation. Advanced biology. 2022;6(5):e2200007.
  41. Gao J, Mei H, Sun J, Li H, Huang Y, Tang Y, et al. Neuropilin‐1‐Mediated SARS‐CoV‐2 Infection in Bone Marrow‐Derived Macrophages Inhibits Osteoclast Differentiation. Advanced Biology. 2022;6(5):2200007.
  42. Fawzy MS, Ashour H, Shafie AAA, Dahman NBH, Fares AM, Antar S, et al. The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. Egyptian Journal of Medical Human Genetics. 2022;23(1):97.
  43. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation research. 2020;126(12):1671-81.
  44. Garcia MA, Johnson SW, Bosch NA, Sisson EK, Sheldrick CR, Kumar VK, et al. Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. Critical care explorations. 2021;3(11):e0566.
  45. Hetta H, Muhammad K, Algammal A, Ramadan H, Abdel-Rahman M, Mabrok M, et al. Mapping the effect of drugs on ACE2 as a novel target site for COVID-19 therapy. European Review for Medical & Pharmacological Sciences. 2021;25(10).
آمار
تعداد مشاهده مقاله: 207
تعداد دریافت فایل اصل مقاله: 114


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب